**Figure 1. Results of the literature research**

|  |
| --- |
| 31 articles identified through PubMed  38 articles after  duplicates removed  25 retained for full review  12 articles interest of the topic  13 articles rejected  11 articles included in the data analysis  1 article rejected due to lack of data  13 articles rejected after  title & abstract reviewed  35 articles identified through MEDLINE |

**Table 1. Demographics and clinical characteristics of 13 SLE patients who later developed Myasthena Gravis, reported in the literature**

|  |  |
| --- | --- |
| Total n | 13 |
| Female, n (%) | 11 (84.6%) |
| Age at SLE onset, mean±SD (years) | 25.6±9.5 |
| Age at MG onset, mean±SD (years) | 33.5±13.7 |
| SLE Duration\*, mean±SD (years) | 8.1±8.2 |
| Race/ethnicity, n (%) |  |
| Caucasian | 1 (7.7%) |
| Black | 3 (23.1%) |
| Hispanic | 1 (7.7%) |
| Asian | 4 (30.8%) |
| Unknown | 4 (30.8%) |
| Total n | 11 |
| ACR criteria for SLE diagnosis, n (%) |  |
| Malar rash | 2 (18.2%) |
| Discoid rash | 3 (27.3%) |
| Photosensitivity | 2 (18.2%) |
| Oral ulcers | 2 (18.2%) |
| Arthritis | 10 (90.9%) |
| Serositis | 6 (54.5%) |
| Renal disorder | 2 (18.2%) |
| Neurological disorder | 4 (36.4%) |
| Haematological disorder | 8 (72.7%) |
| Immunological disorder\*\* | 10 (90.9%) |
| Anti-nuclear antibody (ANA) | 11 (100.0%) |

SLE: Systemic Lupus Erythematosus, MG: Myasthenia Gravis

ACR: American College of Rheumatology

\*SLE duration at time of MG diagnosis

\*\*anti-DNA or anti-Smith, anti-cardiolipin antibodies, or lupus anticoagulant